Liquid Chromatography-Mass Spectrometry Reveals Predictive Metabolomic Biomarkers for Adult Type 1 Diabetes

As metabolomic profiling via machine learning can reveal signatures of host metabolism and identify useful biomarkers, researchers aimed to investigate metabolomic profiles and biomarkers in adult patients with type 1 diabetes (T1D) via machine learning. Serum samples from a group of 29 T1D patients, as well as a corresponding control group, went through metabolomic analysis by liquid chromatography‒mass spectrometry (LC‒MS). A paper based on this research was published in Diabetes, Metabolic Syndrome and Obesity.¹

Fortheir study, the researchers recruited 29 adult patients with T1D and matched them with 29 healthy controls based on age, sex, and body mass index (BMI). Serum samples were collected serum samples from both groups and nontargeted metabolomics was performed using LC‒MS. Four machine learning algorithms (logistic regression, support vector machine, Gaussian naive Bayes, and random forest) were then used for screening potential T1D-related biomarkers.¹

A persistent autoimmune disorder characterized by the destruction of insulin-secreting β-cells in the pancreas, T1D is traditionally associated with pediatric patients, the recognition of adult patients with T1D has increased. ^2-4 Most longitudinal cohort studies on T1D, however, have focused on pediatric populations, which has resulted in a scarcity of data about adult patients.⁴ Studies indicate that approximately 40% of adult patients who are diagnosed with T1D are initially misidentified as having type 2 diabetes (T2D).⁵ Metabolomics has the potential of becoming a useful tool for early diagnosis which can offer insights into the metabolic alterations associated with T1D through comprehensive profiling.⁶

The researchers were able to identify 328 differently abundant metabolites between the T1D group and the control group that were significantly enriched in three metabolic pathways (purine metabolism, ketone body synthesis and degradation, and methyl butyrate metabolism), with probability (P)values less than 0.05. Ten metabolites were identified as T1D-related indicators, including L-fucopyranose, hept-2-ulose, L-rhamnose, docosahexaenoic acid, pumiliotoxin 251d, 9,12-octadecadienal, oleamide, estrane, (e,e)-2,4-heptadienal, and hexadecanamide. The predictive value of the ten candidate metabolites, as measured by the area under the curve (AUC), ranged from 0.86 to 0.95.¹

“In this study,” write the authors of the paper,¹ “we identified purine metabolism, synthesis and degradation of ketone bodies, and impaired methyl butyrate metabolism as metabolic pathways that are altered in adult patients with T1D. Our findings present an extensive profile of metabolic changes in adult patients with T1D, and the identified biomarkers may have important clinical significance in the diagnosis of T1D and the monitoring of responses to therapeutic interventions.”

The researchers recommend that future studies track patients' medication histories, lifestyle, diet, and environment to get more accurate results. A major limitation of this study was the lack of a Type 2 diabetes (T2D) comparison group, making it hard to tell if the patients' physical changes were caused by an autoimmune response or just general blood sugar and insulin issues. However, the patients with Type 1 diabetes (T1D) had different biological markers—such as higher DHA levels—compared to what is typically seen in T2D. This suggests that the metabolic changes in T1D are likely driven by the immune system rather than standard metabolic problems, though future studies directly comparing both types of diabetes are needed to be entirely sure.¹

Read More on Similar Topics
Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets

References

1. Wang, C.; Lan, Y.; Zhao, M. et al. Machine Learning-Based Identification of Serum Metabolic Signatures in Adult Patients with Type 1 Diabetes. Diabetes Metab Syndr Obes. 2026, 19, 569281. DOI: 10.2147/DMSO.S569281
2. Bluestone, J. A.; Buckner, J. H.; Herold, K. C. Immunotherapy: Building a Bridge to a Cure for Type 1 Diabetes. Science 2021, 373 (6554), 510–513. DOI: 10.1126/science.abh1654
3. Chiang, J. L.; Kirkman, M. S.; Laffel, L. M. et al. Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association. Diabetes Care 2014, 37 (7), 2034–2054. DOI: 10.2337/dc14-1140
4. Leslie, R. D.; Evans-Molina, C.; Freund-Brown J, et al. Adult-Onset Type 1 Diabetes: Current Understanding and Challenges. Diabetes Care 2021, 44 (11), 2449–2456. DOI: 10.2337/dc21-0770
5. de Lusignan, S.; Sadek, N.; Mulnier, H. et al. Miscoding, Misclassification and Misdiagnosis of Diabetes in Primary Care. Diabetic Med. 2012, 29 (2), 181–189. DOI: 10.1111/j.1464-5491.2011.03419.x
6. Chai, J.; Sun, Z.; Xu, J. A Contemporary Insight of Metabolomics Approach for Type 1 Diabetes: Potential for Novel Diagnostic Targets. Diab Metabol Syndr Obesity 2022, 1605–1625. DOI: 10.2147/DMSO.S35700